Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

PHASE2TerminatedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions
Breast Cancer
Interventions
DRUG

Tesetaxel

Tesetaxel plus reduced dose of capecitabine

DRUG

Capecitabine

Reduced dose of capecitabine

Trial Locations (25)

2640

Border Medical Oncology, Albury

11733

New York Cancer and Blood Specialists, East Setauket

15006

Hospital Teresa Herrera Materno-Infantil (CHUAC), A Coruña

23502

Virginia Oncology Associates, Norfolk

28040

Fundacion Jimenez Diaz, Madrid

33705

Florida Cancer Specialists and Research Institute, St. Petersburg

33901

Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers

38138

West Cancer Center, Germantown

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

80228

Rocky Mountain Cancer Center, Lakewood

90603

Innovative Clinical Research Institute, Whittier

02215

Dana-Farber Cancer Institute, Boston

H1T 4B3

Hopital Maisonneuve-Rosemont, Montreal

H2X 3E4

Center Hospitalier de Montreal CHUM McPeak Sirois, Montreal

H3T IE2

CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital, Montreal

H4J 3J1

McGill University Health Center, Montreal

G1S 4L8

CHU de Quebec-University Laval, Québec

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre, Sherbrooke

Unknown

Kyungpook National University Hospital, Daegu

National Cancer Center, Goyang

Asan Medical Center, Seoul

Ajou University Hospital, Suwon

Koo Foundation Sun Yat-Sen Cancer Center, Taipei

National Taiwan University Hospital, Taipei

06273

Gangnam Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Odonate Therapeutics, Inc.

INDUSTRY